Deferasirox treatment may be associated with reversible renal Fanconi syndrome.

Abstract

We conducted a dose-escalation study to see if higher doses of Pomalidomide (previously shown to be safe and effective for myelofibrosisassociated anemia at 0.5 mg/day [with prednisone] or 2.0 mg/day) increased anemia responses. 3.0 mg/d given for 21 of 28 consecutive days was the maximum-tolerated dose (MTD), with myelosuppression being dose limiting… (More)
DOI: 10.1002/ajh.21588

2 Figures and Tables

Topics

  • Presentations referencing similar topics